Translational and Clinical Pharmacology最新文献

{"title":"Bioequivalence data analysis.","authors":"Gowooni Park,&nbsp;Hyungsub Kim,&nbsp;Kyun-Seop Bae","doi":"10.12793/tcp.2020.28.e20","DOIUrl":"https://doi.org/10.12793/tcp.2020.28.e20","url":null,"abstract":"<p><p>SAS^® is commonly used for bioequivalence (BE) data analysis. R is a free and open software for general purpose data analysis, and is less frequently used than SAS^® for BE data analysis. This tutorial explains how R can be used for BE data analysis to generate comparable results with SAS^®. The main SAS^® procedures for BE data analysis are PROC GLM and PROC MIXED, and the corresponding R main packages are \"sasLM\" and \"nlme\" respectively. For fixed effects only or balanced data, the SAS^® PROC GLM and R \"sasLM\" provide good estimates; however, for a mixed-effects model with unbalanced data, the SAS^® PROC MIXED and R \"nlme\" are better for providing estimates without bias. The SAS^® and R scripts are provided for convenience.</p>","PeriodicalId":23288,"journal":{"name":"Translational and Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/50/14/tcp-28-175.PMC7781810.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38805066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the pharmacokinetics and food effects of a novel formulation tamsulosin 0.4 mg capsule compared with a 0.2 mg capsule in healthy male volunteers.","authors":"Mu Seong Ban,&nbsp;Yu Kyong Kim,&nbsp;Byungwook Kim,&nbsp;Jina Jung,&nbsp;Yong-Il Kim,&nbsp;Jaeseong Oh,&nbsp;Kyung-Sang Yu","doi":"10.12793/tcp.2020.28.e17","DOIUrl":"https://doi.org/10.12793/tcp.2020.28.e17","url":null,"abstract":"<p><p>Tamsulosin, an alpha-1 adrenoreceptor antagonist, has been used as a primary option for medical treatment of benign prostate hyperplasia. An open-label, single-dose, randomized, three-treatment, three-period, three sequence crossover study was conducted to evaluate the pharmacokinetics (PKs) of 0.2 and 0.4 mg tamsulosin hydrochloride (HCl) in the fed versus the fasted state. Subjects were randomly assigned to three sequences and received one of the following treatments at each period: tamsulosin HCl 0.2 or 0.4 mg in the fed state with a high-fat meal, or tamsulosin HCl 0.4 mg in the fasted state. Blood samples for the PK analysis were collected at pre-dose and up to 48 h post-dose. The PK parameters were calculated by a non-compartmental method. The geometric mean ratio (GMR) and its 90% confidence intervals (CIs) of the plasma maximum concentration (C_max) and area under concentration curve from time zero to last measurable concentration (AUC_last) were calculated. Twenty-two subjects completed the study. The systemic exposure of tamsulosin 0.4 mg decreased approximately 9% in the fed state compared to the fasted state, and the time to reach peak concentration was slightly delayed in the fed state. The dose normalized GMR and its 90% CIs of C_max and AUC_last for 0.2 and 0.4 mg tamsulosin in the fed state were within 0.8 and 1.25 range. Systemic exposure of tamsulosin was decreased in the fed condition compared to the fasted condition. Linear PK profiles were observed between 0.2 and 0.4 mg tamsulosin in the fed state.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT02529800.</p>","PeriodicalId":23288,"journal":{"name":"Translational and Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/b6/tcp-28-181.PMC7781808.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38805067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electronic medical records-based comparison of glycemic control efficacy between sulfonylureas and dipeptidyl peptidase-4 inhibitors added on to metformin monotherapy in patients with type 2 diabetes.","authors":"Suhrin Lee,&nbsp;SeungHwan Lee,&nbsp;In-Jin Jang,&nbsp;Kyung-Sang Yu,&nbsp;Su-Jin Rhee","doi":"10.12793/tcp.2020.28.e21","DOIUrl":"https://doi.org/10.12793/tcp.2020.28.e21","url":null,"abstract":"<p><p>Sulfonylurea (SU) and dipeptidyl peptidase-4 (DPP-4) inhibitors are most common secondary agents that are added to metformin monotherapy. Real-world studies have become increasingly important in providing evidence of treatment effectiveness in clinical practice and real-world data could help appropriate therapeutic information. Therefore, this study aims to compare the glycemic effectiveness of SU and DPP-4 inhibitors, which are added to metformin monotherapy in real clinical practice using electronic medical record (EMR) data. EMR data of type 2 diabetes patients treated at Seoul National University Hospital from December 2002 to December 2012 were retrieved and analyzed. The patients were divided into three groups: patients who maintained metformin monotherapy (M), and patients who added SU (MS) or DPP-4 inhibitors (MD) to metformin monotherapy. The mean change in HbA1c level, the proportion of patients achieving the HbA1c target < 7.0%, proportion of patients with treatment failure, and probability of treatment failure occurrence and changes in prescription were evaluated to compare glycemic control efficacy between SU and DPP-4 inhibitors. The MS showed significantly greater reduction in the Hb1Ac level than MD. The proportion of patients achieving HbA1c < 7.0% is higher in MD, whereas the proportion of patients with treatment failure was greater in MS. The probability of the treatment failure and probability of changes in the prescription were lower in MD than MS with hazard ratio of 0.499 and 0.579, respectively. In conclusion, this real-world study suggested that DPP-4 inhibitors are expected to show more durable glycemic control efficacy than SU in long-term use.</p>","PeriodicalId":23288,"journal":{"name":"Translational and Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/73/tcp-28-199.PMC7781806.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38805069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Introduction to dynamical systems analysis in quantitative systems pharmacology: basic concepts and applications.","authors":"Dongwoo Chae","doi":"10.12793/tcp.2020.28.e12","DOIUrl":"https://doi.org/10.12793/tcp.2020.28.e12","url":null,"abstract":"Quantitative systems pharmacology (QSP) can be regarded as a hybrid of pharmacometrics and systems biology. Here, we introduce the basic concepts related to dynamical systems theory that are fundamental to the analysis of systems biology models. Determination of the fixed points and their local stabilities constitute the most important step. Illustration of a phase portrait further helps investigate multistability and bifurcation behavior. As a motivating example, we examine a cell circuit model that deals with tissue inflammation and fibrosis. We show how increasing the severity and duration of inflammatory stimuli divert the system trajectories towards pathological fibrosis. Simulations that involve different parameter values offer important insights into the potential bifurcations and the development of efficient therapeutic strategies. We expect that this tutorial serves as a good starting point for pharmacometricians striving to widen their scope to QSP and physiologically-oriented modeling.","PeriodicalId":23288,"journal":{"name":"Translational and Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/8c/tcp-28-109.PMC7533163.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38495211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects.","authors":"Wonsuk Shin,&nbsp;A-Young Yang,&nbsp;Hyeonji Yun,&nbsp;Doo-Yeoun Cho,&nbsp;Kyung Hee Park,&nbsp;Hyunju Shin,&nbsp;Anhye Kim","doi":"10.12793/tcp.2020.28.e13","DOIUrl":"https://doi.org/10.12793/tcp.2020.28.e13","url":null,"abstract":"<p><p>Tofacitinib is an oral disease-modifying anti-rheumatic drug to selectively inhibit Janus kinases. Tofacitinib is a representative small molecule inhibitor that is used to treat many diseases including rheumatoid arthritis and various autoimmune conditions. Unlike biological agents, tofacitinib has several advantages, including the ability to be administered orally and a short half-life. This study aimed to evaluate the bioequivalence of the pharmacokinetics (PK) between tofacitinib aspartate 7.13 mg (test formulation) and tofacitinib citrate 8.08 mg (reference formulation; Xeljanz®) in healthy subjects. A randomized, open-label, single-dose, 2-sequence, 2-period, 2-treatment crossover trial was conducted in 41 healthy volunteers. A total of 5 mg of tofacitinib as the test or the reference formulation was administered, and serial blood samples were collected up to 14 hours after dosing for PK analyses. The plasma concentration of tofacitinib was determined by ultra-performance liquid chromatography-tandem mass spectrometry. A non-compartmental analysis was used to estimate the PK parameters. A total of 35 subjects completed the study and the study drug was well-tolerated. The mean maximum concentration (C_max) and area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC_last) for the test formulation were 52.67 ng/mL and 133.86 ng∙h/mL, respectively, and 50.61 ng/mL and 133.49 h∙ng/mL for the reference formulation, respectively. The geometric mean ratios (90% confidence intervals) of the C_max and AUC_last between the 2 formulations were 1.041 (0.944-1.148) and 1.003 (0.968-1.039), respectively. Tofacitinib aspartate exhibited bioequivalent PK profiles to those of the reference formulation.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT04278391.</p>","PeriodicalId":23288,"journal":{"name":"Translational and Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/fa/tcp-28-160.PMC7533161.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38495215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qualification and application of liquid chromatography-quadrupole time-of-flight mass spectrometric method for the determination of carisbamate in rat plasma and prediction of its human pharmacokinetics using physiologically based pharmacokinetic modeling.","authors":"Byeong Ill Lee,&nbsp;Jeong-Hyeon Lim,&nbsp;Min-Ho Park,&nbsp;Seok-Ho Shin,&nbsp;Jin-Ju Byeon,&nbsp;Jang-Mi Choi,&nbsp;Seo-Jin Park,&nbsp;Min-Jae Park,&nbsp;Yuri Park,&nbsp;Young G Shin","doi":"10.12793/tcp.2020.28.e15","DOIUrl":"https://doi.org/10.12793/tcp.2020.28.e15","url":null,"abstract":"<p><p>Carisbamate is an antiepileptic drug and it also has broad neuroprotective activity and anticonvulsant reaction. In this study, a liquid chromatography-quadrupole time-of-flight mass spectrometric (LC-qTOF-MS) method was developed and applied for the determination of carisbamate in rat plasma to support <i>in vitro</i> and <i>in vivo</i> studies. A quadratic regression (weighted 1/concentration²), with an equation y = ax² + bx + c, was used to fit calibration curves over the concentration range from 9.05 to 6,600 ng/mL for carisbamate in rat plasma. Preclinical <i>in vitro</i> and <i>in vivo</i> studies of carisbamate have been studied through the developed bioanalytical method. Based on these study results, human pharmacokinetic (PK) profile has been predicted using physiologically based pharmacokinetic (PBPK) modeling. The PBPK model was optimized and validated by using the <i>in vitro</i> and <i>in vivo</i> data. The human PK of carisbamate after oral dosing of 750 mg was simulated by using this validated PBPK model. The human PK parameters and profiles predicted from the validated PBPK model were similar to the clinical data. This PBPK model developed from the preclinical data for carisbamate would be useful for predicting the PK of carisbamate in various clinical settings.</p>","PeriodicalId":23288,"journal":{"name":"Translational and Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/29/tcp-28-147.PMC7533164.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38495214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting human pharmacokinetics from preclinical data: absorption.","authors":"Dong-Seok Yim,&nbsp;Suein Choi,&nbsp;Soo Hyeon Bae","doi":"10.12793/tcp.2020.28.e14","DOIUrl":"https://doi.org/10.12793/tcp.2020.28.e14","url":null,"abstract":"<p><p>Predicting the rate and extent of oral absorption of drugs in humans has been a challenging task for new drug researchers. This tutorial reviews <i>in vitro</i> and PBPK methods reported in the past decades that are widely applied to predicting oral absorption in humans. The physicochemical property and permeability (typically obtained using Caco-2 system) data is the first necessity to predict the extent of absorption from the gut lumen to the intestinal epithelium (F_a). Intrinsic clearance measured using the human microsome or hepatocytes is also needed to predict the gut (F_g) and hepatic (F_h) bioavailability. However, there are many issues with the correction of the inter-laboratory variability, hepatic cell membrane permeability, CYP3A4 dependency, etc. The bioavailability is finally calculated as F = F_a × F_g × F_h. Although the rate of absorption differs by micro-environments and locations in the intestine, it may be simply represented by k_a. The k_a, the first-order absorption rate constant, is predicted from <i>in vitro</i> and <i>in vivo</i> data. However, human PK-predicting software based on these PBPK theories should be carefully used because there are many assumptions and variances. They include differences in laboratory methods, inter-laboratory variances, and theories behind the methods. Thus, the user's knowledge and experiences in PBPK and <i>in vitro</i> methods are necessary for proper human PK prediction.</p>","PeriodicalId":23288,"journal":{"name":"Translational and Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/f3/tcp-28-126.PMC7533162.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38495212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacodynamic evaluation of YH4808 for <i>Helicobacter pylori</i> eradication in healthy subjects.","authors":"Hyeonsoo Park,&nbsp;Choon Ok Kim,&nbsp;Mikyung Kim,&nbsp;Yeji Lim,&nbsp;Woo Yul Lee,&nbsp;Sukyong Yoon,&nbsp;Min Soo Park","doi":"10.12793/tcp.2020.28.e16","DOIUrl":"https://doi.org/10.12793/tcp.2020.28.e16","url":null,"abstract":"<p><p>YH4808 is a novel selective potassium-competitive acid blocker demonstrated to be safe and to have inhibitory effects against gastric acid secretion in previous studies. A randomized, open-label, multiple-dose, 3-treatment, 1-period, parallel design study was conducted to compare the <i>Helicobacter pylori</i> eradication rates and acid suppression capacities of three regimens in 60 healthy subjects with <i>H. pylori</i>-positive, and the potential of YH4808 to replace proton-pump inhibitors (PPIs) in standard regimens for <i>H. pylori</i> eradication. Group 1 received YH4808, amoxicillin, and clarithromycin as a novel triple regimen, while Group 2 received YH4808 and amoxicillin only, and Group 3 received esomeprazole, amoxicillin, and clarithromycin, as the standard triple regimen. <i>H. pylori</i> eradication rates were 85.0% for Group 1, 25.0% for Group 2, and 83.3% for Group 3. Relative response rate between Group 1 and 3 was 1.02 (0.50-2.07; 95% CI, χ² test <i>p</i> = 0.8881). Furthermore, the novel triple regimen, YH4808, amoxicillin, and clarithromycin, stably inhibited acid secretion and maintained a gastric pH greater than 4 or 5 for 24 hours, which was comparable to the pH range in the standard triple regimen. However, the onset times of the YH4808 regimens were earlier than that for the regimens using esomeprazole. There were no differences in the incidences or severity of adverse events among the three groups. Overall, the novel triple regimen was safe and well-tolerated. YH4808 could replace PPIs in standard triple regimens used for <i>H. pylori</i> eradication.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT01921647.</p>","PeriodicalId":23288,"journal":{"name":"Translational and Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ce/0c/tcp-28-136.PMC7533165.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38495213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetic comparison of two bazedoxifene acetate 20 mg tablet formulations in healthy Korean male volunteers.","authors":"Ji-Sun Yeun,&nbsp;Hye-Su Kan,&nbsp;Minyu Lee,&nbsp;Namsick Kim,&nbsp;Tae-Young Oh,&nbsp;Seung-Kwan Nam,&nbsp;Yoon Seok Choi,&nbsp;In Sun Kwon,&nbsp;Jang Hee Hong","doi":"10.12793/tcp.2020.28.e7","DOIUrl":"https://doi.org/10.12793/tcp.2020.28.e7","url":null,"abstract":"<p><p>Bazedoxifene, used as bazedoxifene acetate, is a selective estrogen receptor modulator that selectively affects the uterus, breast tissue, bone metabolism, and lipid metabolism by antagonizing or enhancing estrogens in the estrogen receptor in the tissue. This study was conducted as an open, randomized, two-period, two-treatment, crossover design to compare the pharmacokinetic (PK) characteristics and tolerability of two bazedoxifene tablets when administered to 50 healthy Korean male volunteers. Enrolled subjects were randomly allocated to 2 sequences of a single oral administration of a test drug and a reference drug, or vice versa with a 14-day washout period between the two doses. Serial blood samples were collected over 96 h for PK analysis. Plasma concentration of bazedoxifene was assayed using liquid chromatography-tandem spectrometry mass. Forty-five participants completed the study with no clinically relevant safety issues. The peak concentrations (C_max, mean ± strandard deviation) of reference drug and test drug were 3.191 ± 1.080 and 3.231 ± 1.346 ng/mL, respectively, and the areas under the plasma concentration-time curve from 0 to the last measurable concentration (AUC_last) were 44.697 ± 21.168 ng∙h/mL and 45.902 ± 23.130 ng∙h/mL, respectively. The geometric mean ratios of test drug to reference drug and their 90% confidence intervals for C_max and AUC_last were 0.9913 (0.8828-1.1132) and 1.0106 (0.9345-1.0929), respectively. The incidence of adverse events between the two formulations was similar. The present study showed that PK and tolerability of two bazedoxifene tablet formulations were comparable when administered to healthy Korean male volunteers.</p><p><strong>Trial registration: </strong>Clinical Research Information Service Identifier: KCT0003978.</p>","PeriodicalId":23288,"journal":{"name":"Translational and Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/eb/tcp-28-102.PMC7327186.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38151698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a method for the simultaneous quantification of endogenous steroids metabolized by CYP3A.","authors":"Yujin Lee,&nbsp;Woori Chae,&nbsp;Seonghae Yoon,&nbsp;Jae-Yong Chung,&nbsp;Joo-Youn Cho","doi":"10.12793/tcp.2020.28.e10","DOIUrl":"https://doi.org/10.12793/tcp.2020.28.e10","url":null,"abstract":"<p><p>Cytochrome P450 (CYP) 3A enzymes, the most important phase 1 drug-metabolizing enzymes, are responsible for 50% of the metabolism of clinically used drugs. CYP3A activity varies widely among individuals, which can affect the probability of adverse drug reactions and drug-drug interactions mediated by the induction or inhibition of the enzyme. Hence, it is important to be able to predict CYP3A activity in individuals to reduce the incidence of unexpected drug responses. To specifically and quickly measure CYP3A activity, we developed method based on gas chromatography interfaced with triple-quadrupole mass spectrometry for the quantification of cortisol, cortisone, 6β-hydroxycortisol, and 6β-hydroxycortisone simultaneously in urine and 4β-hydroxycholesterol in plasma. The results were calculated based on charcoal-stripped steroid-free urine and plasma control samples. The accuracy and precision were 93.18% to 110.0% and 1.96% to 5.34%, respectively. This method was then applied to measure endogenous steroids from urine and plasma samples of healthy Korean males and females. The calibration curves of all analytes showed good linearity with a correlation coefficient (r²) that ranged from 0.9953 to 0.9999. Therefore, this validated method can be used to measure endogenous biomarkers to predict CYP3A activity and might be applicable in the prediction of CYP3A-mediated drug interactions of new drug candidates.</p>","PeriodicalId":23288,"journal":{"name":"Translational and Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/84/tcp-28-73.PMC7327190.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38151694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}